Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAC1 | P63000 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19988835 | 0.91 | MAPT (0.46) | MAPTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL25796640 | 0.90 | MAPT (0.49) | MAPTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL19991598 | 0.82 | MAPT (0.49) | MAPTALDH1A1PKMSMN1; SMN2HTT | |
| Toluene SCHEMBL23360724 | 0.81 | MAPT (0.48) | MAPTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21001116 | 0.80 | MAPT (0.51) | MAPTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6624247 | 0.80 | MAPT (0.55) | MAPTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL16532774 | 0.80 | SIRT6 (0.54) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2062256 | 0.80 | P2RY12 (0.40) | MAPTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2589998 | 0.80 | MAPT (0.69) | MAPTALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2060641 | 0.80 | MAPT (0.53) | MAPTALDH1A1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691970-B2 | Pyrazolopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-11691970-B2 | Pyrazolopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-11691970-B2 | Pyrazolopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| CN-111655690-B | Pyrazolopyridinone compounds | 詹森药业有限公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-3713941-B1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-22 | — | — | EP | disclosed |
| EP-3713941-B1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-22 | — | — | EP | disclosed |
| US-20210147411-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-20 | — | — | US | disclosed |
| US-20210147411-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-20 | — | — | US | disclosed |
| EP-3713941-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2020-09-30 | — | — | EP | disclosed |
| CN-111655690-A | Pyrazolopyridinone compounds | 詹森药业有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20090143369-A1 | METHODS OF USING SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| US-7501414-B2 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2009-03-10 | — | — | US | disclosed |
| EP-1727809-B8 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2008-10-29 | — | — | EP | disclosed |
| EP-1947093-A1 | Substituted morpholine and thiomorpholine derivatives | H. Lundbeck A/S (DK) | 2008-07-23 | — | — | EP | disclosed |
| EP-1727809-B1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1727809-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H.Lundbeck A/S (DK) | 2006-12-06 | — | — | EP | disclosed |
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| WO-2005087754-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | OPRM1, OPRK1, OPRD1 | MAPT 169/4885ALDH1A1 1668/4885CYP1A2 82/4885 |
| US-20090137571-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRD1 | MAPT 176/4885ALDH1A1 1816/4885CYP1A2 99/4885 |
| US-20210147411-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | FGFR1, FGFR3, FGFR2 | MAPT 1516/4885ALDH1A1 1418/4885CYP1A2 1486/4885 |
| US-20090143369-A1 | METHODS OF USING SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | OPRM1, TPMT, OPRK1 | MAPT 264/4885ALDH1A1 1400/4885CYP1A2 70/4885 |
| US-11691970-B2 | Pyrazolopyridinone compounds | FGFR1, FGFR3, FGFR2 | MAPT 1516/4885ALDH1A1 1418/4885CYP1A2 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.